uniQure N.V. (QURE) Stock Ratings

View Stock Quote:

Login Required

You must login before you can rate this stock.

Login Now

Community Rating:

Not Rated

No Current Ratings
View All-Time Ratings

Do the wall street analysts agree?

Consensus Recommendation:

View detailed analyst research

Other Member Ratings

View Most Rated Stocks

Member Call Date Rated Timeframe Start Price End Price Stock Gain/Loss Score Status
Chrisyahahha Chrisyahahha 10/21/2015 3 months $17.10 $15.83 -7.43% 7 Ended
laurvp laurvp 08/20/2015 3 months $26.21 $17.67 -32.58% 32 Ended
DrMedicalValue DrMedicalValue 05/24/2015 1 Year $26.43 $12.12 -54.14% -54 Ended
Comments: Disruptive validated tech platform that does not reduce symptoms but QURES!
goedbegingoedbegin goedbegingoedbegin 04/14/2015 1 Year $29.76 $12.79 -57.02% -57 Ended
Comments: undervalued
ashu210890 ashu210890 04/08/2015 1 month $33.16 $27.56 -16.89% -16 Ended
Work Smarter Not Harder Work Smarter Not Harder 03/20/2015 1 Year $27.55 $11.14 -59.56% -59 Ended
Comments: Price for a treatment, company is undervalued
MLL MLL 02/12/2015 1 Year $19.49 $14.25 -26.89% -26 Ended
Comments: undervalued
just profit just profit 01/15/2015 1 Year $20.32 $15.83 -22.1% -22 Ended
Comments: First gene therapy drug Glybera on the market by UniQure!

Neither The NASDAQ OMX Group, Inc. nor any of its affiliates (collectively "NASDAQ OMX") makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Investment related advice and comments are solely those of the individuals who publish them and do not in any way represent the opinions of NASDAQ OMX. Investors should undertake their own due diligence and carefully evaluate companies before investing.